Buy Sibelium (Flunarizine 5/10mg) Online - Calcium Channel Blocker for Migraine Prophylaxis and Vertigo

Sibelium (Flunarizine 5mg or 10mg by Janssen Pharmaceutica / Johnson & Johnson) is a calcium channel blocker used for migraine prevention (prophylaxis) and vertigo management. Unlike Depakote (anticonvulsant) or acute triptans like Maxalt and Imitrex, Sibelium works through an entirely different mechanism — blocking calcium channels in cerebral blood vessels and neurons to prevent the neurovascular instability that triggers migraines. Widely used across Europe, Asia, Latin America and Canada for decades (not FDA-approved in the US, which is why it remains less familiar to American patients), flunarizine is considered a first-line preventive option in many international headache guidelines. Its once-daily bedtime dosing, sedating profile (which helps sleep-related migraines), and dual effectiveness for both migraine prevention AND vestibular disorders (vertigo, Meniere's disease) make it uniquely versatile. This guide covers the preventive approach with focus on the calcium channel blocker mechanism, the once-daily bedtime protocol, the required treatment breaks to prevent neurological side effects, and when Sibelium is preferred over Depakote or other preventive options.

Sibelium as preventive therapy:

• Taken once daily at bedtime (not during attacks)
• Reduces migraine frequency over 2-3 months
• Reduces attack severity when they still occur
• Reduces attack duration
• Does NOT stop an active migraine (use acute medication for that)
• Also prevents vertigo attacks (dual benefit)
• Requires 6-12 month treatment course with mandatory breaks

• Does not stop an active migraine attack in progress
• Does not work immediately (takes 2-3 months for full effect)
• Does not eliminate all migraines (typical goal is 50% reduction)
• Does not replace lifestyle trigger management
• Does not cure the underlying migraine tendency

Flunarizine works on multiple levels:

• Blocks calcium overload in cerebral blood vessels
• Prevents vessel spasm associated with migraine aura
• Stabilizes neuronal membranes reducing cortical hyperexcitability
• Reduces vestibular nucleus overactivity (vertigo benefit)
• Mild antihistamine activity (contributes to sedation)
• Weak dopamine receptor antagonism (source of some side effects)

✅ Sibelium is appropriate if you:

• Have 4+ migraine days per month
• Need preventive (not acute) treatment
• Have vestibular migraine (migraine with vertigo)
• Have Meniere's disease
• Cannot tolerate other preventive medications
• Prefer once-daily dosing
• Would benefit from sedating effect (nighttime dosing helps sleep)
• Are committed to 3-month trial for full effect
• Understand need for treatment breaks
• Do NOT have history of depression
• Do NOT have Parkinson's disease or movement disorders

🚨 Do NOT use Sibelium if you:

• Have current or history of clinical depression
• Have Parkinson's disease
• Have other extrapyramidal movement disorders
• Are pregnant or trying to conceive
• Are breastfeeding
• Have severe liver disease
• Are allergic to flunarizine
• Take MAOIs
• Have history of neuroleptic malignant syndrome

Bedtime dosing is specifically recommended because:

• Flunarizine has sedating properties
• Taking at bedtime avoids daytime drowsiness
• The sedative effect helps with sleep quality
• Long half-life means once-daily is sufficient
• Peak levels overnight when body is at rest

Timeline for effectiveness:

• First 2-4 weeks: minimal migraine change (drug building up)
• 4-8 weeks: initial improvement typically noted
• 2-3 months: full preventive effect established
• 3-6 months: continued benefit assessment
• 6-12 months: reevaluate for continued need

🚨 Sibelium requires mandatory treatment breaks — typically 4-8 weeks off after every 6-12 months of continuous use.

This is critical to prevent accumulation-related neurological side effects.

During break period:

• Have acute medication (triptan) available for breakthroughs
• Track migraine frequency
• Assess whether preventive still needed
• Consider alternative preventive if migraines return
• Many patients maintain reduced frequency temporarily off medication

• Sedation/drowsiness (most common, why taken at bedtime)
• Weight gain (significant concern, 3-10 kg possible)
• Increased appetite
• Fatigue during day
• Dry mouth
• Nasal congestion
• Mild depression symptoms (monitor carefully)

Weight gain is common with Sibelium. Strategies to minimize:

• Anticipate increased appetite — do not give in
• Structured meal times, avoid grazing
• Track weight weekly
• Increase physical activity
• Limit carbohydrates and sugar
• Discuss significant weight gain with doctor (may warrant switching)

🚨 Depression is a known side effect. If you experience persistent low mood, loss of interest, sleep changes, feelings of hopelessness, or suicidal thoughts, contact doctor immediately — may need to discontinue Sibelium.

🚨 Long-term use of flunarizine can cause drug-induced parkinsonism and tardive dyskinesia.

This is why treatment breaks are mandatory and duration limits exist.

Involuntary movements of face, tongue, lips, jaw, or extremities. May be persistent even after stopping medication. Report ANY unusual involuntary movements immediately.

If parkinsonian or dyskinetic symptoms develop:

• Stop flunarizine immediately
• Contact doctor same day
• Do not restart flunarizine
• Consider alternative preventive medications
• Neurological evaluation recommended
• Most symptoms resolve within weeks to months after stopping

Sibelium uniquely benefits patients with vestibular migraine — migraine with prominent dizziness/vertigo component. It treats both the migraine headache AND the vertigo simultaneously, unlike other preventive medications requiring separate treatment.

Do NOT combine with:

• MAOIs (phenelzine, tranylcypromine, selegiline)
• Other dopamine receptor blockers (typical/atypical antipsychotics)
• Metoclopramide (also dopamine blocker)
• Prochlorperazine (compazine)

Alcohol should be minimized during Sibelium treatment. Combined with flunarizine's sedating effects, alcohol impairs coordination, thinking, and reaction time. Additionally, alcohol is a common migraine trigger — defeating the purpose of preventive therapy.

🚨 Sibelium should NOT be used during pregnancy.

Not recommended during breastfeeding. Flunarizine is likely excreted in breast milk and could affect infant.

• Room temperature 15-30°C
• Original packaging with cap tight
• Away from bathroom humidity
• Away from direct sunlight
• Away from heat sources
• Out of reach of children

Flunarizine is widely used across Europe (approved since 1980s), Latin America, Asia, and Canada as first-line migraine prevention. It is NOT FDA-approved in the United States, though this is due to regulatory factors rather than safety or efficacy concerns. International headache guidelines consistently include flunarizine among recommended preventive options.

• Vestibular migraine (dual vertigo benefit)
• Meniere's disease with migraines
• Once-daily dosing preferred
• Sedating effect helpful (insomnia component)
• Blood monitoring not desired (unlike Depakote)
• Cannot tolerate weight-loss side effects (topiramate)
• No depression history

• History of depression: avoid Sibelium; try topiramate or CGRP antagonists
• Concerned about weight gain: topiramate (weight loss) or CGRP
• Concurrent hypertension: propranolol (dual benefit)
• Bipolar disorder: Depakote (dual benefit)
• Older age with movement disorder risk: avoid Sibelium; consider CGRP
• Pregnancy planning: avoid Sibelium (long half-life); consider beta blocker

• Vestibular migraine or Meniere's component
• Prefer once-daily dosing
• Sleep-onset migraines (bedtime sedation helpful)
• Cannot tolerate frequent blood draws
• Failed Depakote trial
• Concerned about Depakote liver monitoring

• History of depression (Sibelium contraindicated)
• Concurrent seizure disorder
• Concurrent bipolar disorder (dual benefit)
• Cannot tolerate mandatory Sibelium breaks
• Failed Sibelium trial

Do not wait for scheduled appointment for:

• Any unusual involuntary movements (face, tongue, limbs)
• Tremor development
• Muscle stiffness or slowness of movement
• Persistent depression or hopelessness
• Suicidal thoughts
• Severe allergic reactions
• Excessive weight gain (over 5 kg in first months)

Medical disclaimer: This guide provides general usage information for Sibelium (flunarizine 5mg or 10mg by Janssen Pharmaceutica) and does not replace individualized medical advice. Sibelium is a calcium channel blocker used for migraine PREVENTION (prophylaxis) — taken daily to reduce migraine frequency, NOT to abort active attacks. Full preventive effect requires 2-3 months of continuous daily dosing at bedtime. Sibelium also uniquely treats vestibular disorders (vertigo, Meniere's disease). NOT FDA-approved in the United States but widely used and considered first-line preventive across Europe, Asia, Latin America, and Canada. ABSOLUTELY CONTRAINDICATED in patients with current or history of clinical depression, Parkinson's disease, or other movement disorders. MANDATORY treatment breaks (4-8 weeks off) required after every 6-12 months of continuous use to prevent accumulation-related drug-induced parkinsonism and tardive dyskinesia. These serious neurological side effects are why patient selection matters and duration limits exist. Common side effects include weight gain (significant, 3-10 kg), sedation (why taken at bedtime), and depression (monitor carefully — stop immediately if mood changes develop). Do not combine with MAOIs, dopamine receptor blockers, or other antipsychotic medications. Not for use during pregnancy (long half-life of approximately 18 days means residual drug persists weeks after discontinuation — discontinue at least 4-8 weeks before attempting conception). Not for breastfeeding. Report ANY unusual involuntary movements, tremor, muscle rigidity, or mood changes immediately. Sibelium is preferred over other preventive options in patients with vestibular migraine or Meniere's disease due to dual mechanism benefit. Manufactured by Janssen Pharmaceutica, subsidiary of Johnson & Johnson, one of the world's largest pharmaceutical companies with global quality standards.